1. ALLA AKTIER
  2. NYHETER
  3. NEWBURY PHARMACEUTICALS

Newbury Pharmaceuticals

Nyheter Newbury Pharmaceuticals Nyheter alla bolag
Slipp dessa annonser och få en massa andra godsaker med vårt premiumabonnemang.

Newbury Pharmaceuticals brings forward interim report for third quarter 2022/2023 from July 7 to June 14

MARKN.

Newbury Pharmaceuticals has previously announced that the interim report for the period September 2022 – May 2023 will be published on July 7. The board has now decided to advance the report date to June 14.

The reason for this decision is that work on the report has gone faster than expected and is available for publication.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

Newbury Pharmaceuticals brings forward interim report for third quarter 2022/2023 from July 7 to June 14

Datum 2023-06-13, kl 17:40
Källa MFN
Bifogade filer
Newbury Pharmaceuticals brings forward interim report for third quarter 2022/2023 from July 7 to June 14